1. HBW Insight
  2. >>Geography
  3. >>International

J&J's Manoj Raghunandanan On Becoming A 'Digital First' Consumer Health Company

 
• By David Ridley

“We want to make sure digital is embedded into every aspect of our business, from R&D and supply chain, to marketing and finance,” says Johnson & Johnson's president of global self-care and consumer experience organization Manoj Raghunandanan in this exclusive interview.  

• Source: J&J

Johnson & Johnson’s consumer health business will next year follow companies like Haleon, Perrigo and Bausch + Lomb Inc down the path of becoming a pure self-care company.

Under the brand name Kenvue – a combination of the word “ken,” which means knowledge in Scottish, and “vue,” implying sight – the consumer business is expected to be spun off from J&J in 2023

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

More from Geography

OTCs Are ‘Beacon Of Hope’ For Austrian Pharmacy

 
• By David Ridley

Just under half of Austrian pharmacists surveyed by Elpato Medien are “convinced that the OTC business will ensure the survival of their pharmacy.”

Melatonin And Buccal Acyclovir On German Switch Committee Agenda

 
• By David Ridley

An application for melatonin as an OTC medicine is on the agenda for the next German switch committee meeting, despite the hormone being widely available in food supplements. Acyclovir as a buccal tablet and second-generation antihistamine rupatadine are also up for discussion.

Over The Counter: Brands, Brexit And New Self-Care Business Models, With PAGB’s Michelle Riddalls

 
• By David Ridley

HBW Insight catches up with UK OTC industry association CEO Michelle Riddalls to talk about digital self-care and the unrealized promise of Brexit - part 2.